Trial NCT02772003

DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection

This phase I trial studies the side effects and best dose of deoxyribonucleic acid (DNA)
vaccine therapy in treating patients with hepatitis C virus (HCV) infection that persists or
progresses over a long period of time. Vaccines made from DNA may help the body build an
effective immune response to kill cancer cells that express HCV infection.

Intervention

DNA Plasmid Encoding Interleukin-12 INO-9012, Electroporation-Mediated Plasmid DNA Vaccine Therapy, HCV DNA Vaccine INO-8000, Laboratory Biomarker Analysis, Quality-of-Life Assessment

Condition

Chronic Hepatitis, Hepatitis C Infection

Investigators

Lewis R. Roberts, Marcia R. Cruz-Correa, Jeffrey Jacobson, Surakit Pungpapong

See list of participating sites